Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S333000, C514S338000, C514S297000, C546S152000, C546S256000, C546S275700, C548S312400
Reexamination Certificate
active
07141581
ABSTRACT:
Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
REFERENCES:
patent: 5621082 (1997-04-01), Xiong et al.
patent: 5705499 (1998-01-01), Cywin et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5861414 (1999-01-01), Allen
patent: 5886195 (1999-03-01), Tang et al.
patent: 6534524 (2003-03-01), Kania et al.
patent: 273 062 (1989-11-01), None
patent: 0 066 270 (1982-08-01), None
patent: 0 816 357 (1998-01-01), None
patent: WO 86/05779 (1986-10-01), None
patent: WO 93/19052 (1993-09-01), None
patent: WO 96/14843 (1996-05-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 97/03967 (1997-02-01), None
patent: WO 97/16447 (1997-05-01), None
patent: WO 97/34876 (1997-09-01), None
patent: WO 97/48697 (1997-12-01), None
patent: WO 98/09961 (1998-03-01), None
patent: WO 98/14451 (1998-04-01), None
patent: WO 99/21845 (1999-05-01), None
patent: WO 99/23076 (1999-05-01), None
patent: WO 99/23077 (1999-05-01), None
patent: WO 00/18761 (2000-04-01), None
patent: WO00/37107 (2000-06-01), None
patent: WO00/38665 (2000-07-01), None
patent: WO00/38715 (2000-07-01), None
patent: WO00/38716 (2000-07-01), None
patent: WO00/38717 (2000-07-01), None
patent: WO00/38718 (2000-07-01), None
patent: WO00/38719 (2000-07-01), None
patent: WO00/38730 (2000-07-01), None
patent: WO00/38786 (2000-07-01), None
Bertolini et al., “Endostatin, an antiangiogenic drug, induces tumor stabilitzation after chemotherapy . . . non-Hodgkin lumphoma,”Blood, 2000, 96, 282-287.
Bruggen et al., “VEGR Antagonism Reduces Edema Formation and Tissue Damage after Ischemia/Reperfusion Injury in the Mouse Brain,” 1999, 104; 1613-1620.
Monestiroli, Silva, “Kinetics and Viability of Circulating Endothelial Cells As Surrogate Angiogenesis Marker in an Animal Model of Human Lumphoma,”Cancer Research, 2001, 61, 4341-4344.
Nasmyth, Kim, “Viewpoint: Putting the Cell Cycle in Order,”Science, 1996, 274, 1643-1645.
Strawn et al., “Flk-1 as a target for tumor growth inhibition,”Cancer Research, 1996, 56, 3540-3545.
Al-Khodairy et al.,Molec. Biol. Cell, 5, 147-160 (1994).
Alon et. al,Nat. Med., 1, 1024 (1995).
Bolen,Oncogene, 8, 2025-2031 (1993).
Bunz et al.,Science, 282, 1497 (1998).
Castro et al.,J. Med Chem, 39:842-849 (1996).
Cohen,Curr. Op. Chem. Biol., 3, 459-65 (1999).
Folkman,Nature Med., 1, 27-31 (1995).
Hartwell et al.,Science, 266, 1821-1828 (1994).
Hartwell et al.,Science, 246, 629-634 (1989).
Holash et al.,Oncogene, 18, 5356-62 (1999).
Jeffrey et al.,Nature, 376, 313-320 (Jul. 27, 1995).
Kamb,Trends in Genetics, 11, 136-140 (1995).
Kamb et al.,Science, 264, 436-440 (1994).
Katsura et al.,Chem Pharm Biol, 40(8), 2062-2074-140 (1992).
Klohs et al.,Curr. Op. Chem. Biol., 10, 544-49 (1999).
Klunder et al.,J. Med Chem, 41, 2960-2971 (1998).
Lee et al.,Biochem, 23, 4255 (1984).
Lin et al.,J Med Chem., 15(6), 615 (1972).
Lutty and McLeod,Arch. Ophthalmol., 110, 267 (1992.
Maisonpierre et al.,Science, 277, 55-60 (1997).
Matsuoka,Science, 282, 1893-1897 (1998).
McMahon et al.,Current Opinion in Drug Discovery&Development, 1, 131-146 (1998).
McMahon et al,Oncologist, 5, 3-10 (2000).
Merenmines et al.,Cell Growth&Differentiation, 8, 3-10 (1997).
Millauer et al.,Cancer Research, 56, 1615-1620 (1996).
Mohammadi et al.,EMBO Journal, 17, 5896-5904 (1998.
Mohammadi et al.,Mol. Cell. Biol., 16, 977-989 (1996).
Mylari et al.,J. Med. Chem., 35, 457-465 (1992).
Nurse,Cell, 91, 865-867 (1997).
O'Connor,Cancer Surveys, 29, 151-182 (1997).
Parast et al.,BioChemistry, 37, 16788-16801 (1998).
Peng et al.,Science, 277, 1501-1505 (1997).
Penn et al,Invest. Ophthalmol. Vis. Sci., 36, 2063, (1995).
Rosenblatt et al.,J. Mol. Biol., 230, 1317-1319 (1993).
Rosowsky et al,J. Med Chem., 31, 763-768 (1988).
Sanchez et al.,Science. 277, 1497-1501 (1997).
Sarodnick et al,J. Prakt. Chem. 339, 714-720 (1997).
Still et al.,J. Org. Chem., 43, 2923 (1978).
Stone et al,J. Neurosci., 15, 4738 (1995).
Strawn et al.,Exp. Opin. Invest. Drugs, 7, 553-573 (1998).
Thomas et al.,J. Biol. Chem., 274, 36684-92 (1999).
Thompson,Oncogene, 15, 3025-3035 (1997).
Walworth et al.,Nature, 363, 368-371 (1993).
Weinert,Science, 277, 1450-1451 (1997).
Whitney et al., DNA Cell Biol 9, 823-830, 1993.
Winters et al.,Oncogene, 17, 673-684 (1998).
Yoshiji et al.,Cancer Research, 57, 3924-3928 (1997).
Zeng et al.,Nature, 395, 507-510 (1998).
Bender Steven
Hu-Lowe Dana
Shalinsky David Ray
Agouron Pharmaceuticals , Inc.
Davis Zinna N.
Pugmire Matthew J.
Zielinski Bryan C.
LandOfFree
Indazole compounds and pharmaceutical compositions for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazole compounds and pharmaceutical compositions for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole compounds and pharmaceutical compositions for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3671805